Keensight Capital, a private equity manager, has acquired a majority stake in regenerative medtech company Isto Biologics from Thompson Street Capital Partners.
Isto Biologics develops and manufactures orthobiologic products to aid the healing process, according to a Sept. 17 news release from Thompson Street Capital Partners.
Keensight will continue to accelerate Isto’s growth strategy through organic expansion and acquisitions.
More than 400 hospitals and clinics, primarily in the U.S., purchase products from Isto Biologics.
Thompson Street Capital Partners will retain a minority stake alongside Isto Biologics’ management team, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.